scholarly journals Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial

2016 ◽  
Vol 2 (1) ◽  
Author(s):  
Kerin Adelson ◽  
Bhuvaneswari Ramaswamy ◽  
Joseph A Sparano ◽  
Paul J Christos ◽  
John J Wright ◽  
...  
Keyword(s):  
Breast Cancer ◽  
New York ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Aromatase Inhibitors ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Hormone Receptor Positive ◽  
Randomized Phase Ii

scholarly journals Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205

2009 ◽  
Vol 20 (4) ◽  
pp. 642-647 ◽  
Author(s):  
T. Li ◽  
P.J. Christos ◽  
J.A. Sparano ◽  
D.L. Hershman ◽  
S. Hoschander ◽  
...  
Keyword(s):  
Breast Cancer ◽  
New York ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Farnesyltransferase Inhibitor ◽  
Hormone Receptor Positive

scholarly journals Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer

2011 ◽  
Vol 17 (21) ◽  
pp. 6822-6830 ◽  
Author(s):  
Nuhad K. Ibrahim ◽  
Kemal O. Yariz ◽  
Ihor Bondarenko ◽  
Alexei Manikhas ◽  
Vladimir Semiglazov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Hormone Receptor Positive ◽  
Randomized Phase Ii

A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 1046-1046 ◽  
Author(s):  
Toshimi Takano ◽  
Chiyo K. Imamura ◽  
Kenji Tamura ◽  
Shigehira Saji ◽  
Takeharu Yamanaka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Cyp2d6 Genotype ◽  
Hormone Receptor Positive ◽  
Randomized Phase Ii

scholarly journals LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)

2021 ◽  
Vol 32 ◽  
pp. S1291-S1292
Author(s):  
M. Oliveira ◽  
R.D. Baird ◽  
R.A.B. Voorthuis ◽  
L. De Boo ◽  
A.G.J. van Rossum ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Hormone Receptor Positive ◽  
Randomized Phase Ii

scholarly journals A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (48) ◽  
pp. 84224-84236 ◽  
Author(s):  
Yannan Zhao ◽  
Chengcheng Gong ◽  
Zhonghua Wang ◽  
Jian Zhang ◽  
Leiping Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Aromatase Inhibitors ◽  
Hormone Receptor ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
Hormone Receptor Positive ◽  
Randomized Phase Ii

Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor–Positive, Metastatic Carcinoma of the Breast in Premenopausal Women

2010 ◽  
Vol 28 (25) ◽  
pp. 3917-3921 ◽  
Author(s):  
Robert. W. Carlson ◽  
Richard Theriault ◽  
Christine M. Schurman ◽  
Edgardo Rivera ◽  
Cathie T. Chung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Antitumor Activity ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Hot Flashes ◽  
Metastatic Breast ◽  
Premenopausal Women ◽  
Hormone Receptor Positive

Purpose To explore the antitumor activity of the aromatase inhibitor, anastrozole, in the treatment of premenopausal women with hormone receptor–positive, metastatic breast cancer who have been rendered functionally postmenopausal with the use of the luteinizing hormone-releasing hormone agonist, goserelin. Patients and Methods Premenopausal women with estrogen and/or progesterone receptor–positive, metastatic or recurrent breast cancer were enrolled in this prospective, single-arm, multicenter phase II trial. Patients were treated with goserelin 3.6 mg subcutaneous monthly and began anastrozole 1-mg daily 21 days after the first injection of goserelin. Patients continued on treatment until disease progression or unacceptable toxicity. Results Thirty-five patients were enrolled of which 32 were evaluable for response and toxicity. Estradiol suppression was assessed, with mean estradiol levels of 18.7 pg/mL at 3 months and 14.8 pg/mL at 6 months. One participant (3.1%) experienced a complete response, 11 (34.4%) experienced partial response, and 11 (34.4%) experienced stable disease for 6 months or longer for a clinical benefit rate of 71.9%. Median time to progression was 8.3 months (range, 2.1 to 63+) and median survival was not been reached (range, 11.1 to 63+). The most common adverse events were fatigue (50%), arthralgias (53%), and hot flashes (59%). There were no grade 4 to 5 toxicities. Conclusion The combination of goserelin plus anastrozole has substantial antitumor activity in the treatment of premenopausal women with hormone receptor–positive metastatic breast cancer.

Sign in / Sign up

Export Citation Format

Share Document